RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an oxymetazoline hydrochloride ophthalmic solution, for the treatment of acquired blepharoptosis, or low-lying eyelid in adults. The company was formerly known as Osmotica Pharmaceuticals plc and changed its name to RVL Pharmaceuticals plc in January 2022. RVL Pharmaceuticals plc is headquartered in Bridgewater, New Jersey.
IPO Year: 2018
Exchange: NASDAQ
Website: https://www.rvlpharma.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/21/2022 | $2.50 | Hold | Jefferies |
| 4/5/2022 | $4.00 | Overweight | Barclays |
Jefferies resumed coverage of RVL Pharmaceuticals with a rating of Hold and set a new price target of $2.50
Barclays resumed coverage of RVL Pharmaceuticals with a rating of Overweight and set a new price target of $4.00
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M
BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: DateThursday, May 11, 2023Time 8:30 a.m. ETToll free (U.S.)800-579-2543International 7
-- RVLP records exceptional year-over-year growth with UPNEEQ® launch into the medical aesthetics market -- -- Full year 2022 total revenues of $49.7 million, an increase of $32.2 million, or 184%, over 2021 -- -- Full year 2022 UPNEEQ net product sales of $34.2 million, an increase of $26.7 million, or 356%, over 2021 -- -- Preliminary fourth quarter 2022 UPNEEQ net product sales were $12.1 million; refinement to revenue methodologies results in final fourth quarter 2022 UPNEEQ net product sales of $9.8 million, an increase of $6.7 million, or 216%, over 2021; $2.3 million now recognized in first quarter 2023 -- BRIDGEWATER, N.J., March 20, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceutical
BRIDGEWATER, N.J., March 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its fourth quarter and full year 2022 financial results and provide a commercial update on Monday, March 20, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: DateMonday, March 20, 2023Time8:30 a.m. ETToll free (U.S.)800-343-4136In
BRIDGEWATER, N.J., Nov. 03, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its third quarter 2022 financial results and provide a commercial update on Thursday, November 10, 2022, after the close of the U.S. financial markets. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows: Date Time Toll free (U.S.)In
-- Second quarter 2022 UPNEEQ® net product sales of $8.4 million; 42% above first quarter -- -- Opportunity for cash runway to extend through 2023 following recently announced financings -- -- Expanded Board of Directors with the appointment of Alisa Lask, Aesthetic industry veteran with pharmaceutical experience in both sales and marketing -- -- Continued sequential expansion among key UPNEEQ demographics, including pharmacy-paid prescribers and medical aesthetics practices -- BRIDGEWATER, N.J., Aug. 11, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced financial results and business highlights
BRIDGEWATER, N.J., Aug. 04, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2022 financial results and provide a commercial update on Thursday, August 11, 2022, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Interim Chief Financial Officer, will host a conference call as follows: Date Thursday, August 11, 2022Time 8:30 a.m. ETRegister* (audio only) Click HereW
First quarter 2022 UPNEEQ net product sales of $5.9 million; 90% growth over fourth quarter 2021 First quarter 2022 total revenues of $21.4 million, inclusive of $15.5 million from Santen License Agreement, with related cash receipt in April 2022 Reaffirms fourth quarter 2022 UPNEEQ net product sales guidance of $20 to 25 million UPNEEQ selected as the winner of a "Best in Innovation" award in the 12th Annual Beauty Awards conducted by NewBeauty, a Sandow Publication and "Best Professional Treatment Product" in the Shape Healthy Beauty Awards BRIDGEWATER, N.J., May 12, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical co
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
4 - RVL Pharmaceuticals plc (0001739426) (Issuer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
25-NSE - RVL Pharmaceuticals plc (0001739426) (Subject)
DEF 14A - RVL Pharmaceuticals plc (0001739426) (Filer)
PRE 14A - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
8-K - RVL Pharmaceuticals plc (0001739426) (Filer)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13D/A - RVL Pharmaceuticals plc (0001739426) (Subject)
SC 13G/A - RVL Pharmaceuticals plc (0001739426) (Subject)
Lender to Provide Incremental Liquidity to Support Long-Term Growth Senior Secured Lender to Exchange Outstanding Debt into Equity of the Reorganized Entities Business Operations at U.S. Subsidiaries to Continue as They Pursue Strategic Plan RVLP Ordinary Shares Expected to be Cancelled BRIDGEWATER, N.J., Oct. 12, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc ("RVL" or "the Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy eyelid, in adults, today announced that certain of its U.S. operating subsidiaries, RevitaLid Pharmaceutical C
BRIDGEWATER, N.J., Aug. 23, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced that Brian Markison, Chief Executive Officer, will participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 25th Annual Global Investment Conference in New York City as follows: Date:Tuesday, September 12, 2023 Time:11:30 am ET Webcast:Click here To schedule a 1x1 investor meeting with the Company, please contact [email protected] at H.C. Wainwright. The live and archived webcast of the fireside chat will be accessible from the Company's website at www.rvlpharma.com, under the Investors & New
BRIDGEWATER, N.J., Aug. 16, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults, today announced that it has entered into definitive agreements for the purchase and sale of 11,870,846 of its ordinary shares (or ordinary share equivalents in lieu thereof) at a purchase price of $0.4212 per ordinary share (or ordinary share equivalent in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules. The Company also agreed
-- UPNEEQ® remains a significant potential value driver given its rapid early acceptance by providers, large total addressable market and untapped consumer opportunity -- -- Executed financing amendment with Athyrium, which, subject to certain conditions, would provide meaningful flexibility as part of our ongoing strategy to invest in UPNEEQ and drive growth -- -- The Company is in discussions with strategic targets that could accelerate UPNEEQ sales, broaden the Company's portfolio and leverage the field force investment -- -- Second quarter 2023 UPNEEQ net product sales of $8.3 million and operating expenses of $14.4 million, down 2% and 32%, respectively, compared to the prior year pe
BRIDGEWATER, N.J., Aug. 02, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its second quarter 2023 financial results and provide a commercial update on Monday, August 14, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: Date Monday, August 14, 2023Time 8:30 a.m. ETRegister* (audio only) Click hereW
BRIDGEWATER, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company organized in Ireland focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or droopy or low-lying eyelids, in adults, today announced that, as authorized by the Board of Directors, the Company has been considering certain strategic alternatives. These include discussions to acquire a specific potential counterparty in an all stock strategic transaction and discussions with potential financing sources regarding incremental funding for the combined co
BRIDGEWATER, N.J., June 15, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, today announced results of the proposal to approve a waiver of offer obligations under Rule 9 of the Irish Takeover Rules (the "Rules") at the Company's Annual General Meeting held on June 15, 2023 (the "AGM"). At the AGM, the resolution placed before the meeting in respect of the approval of a waiver of offer obligations under Rule 9 of the Rules to enable the acquisition of ordinary shares by the Company's major shareholders and certain members of its management team was duly passed by independent shareholders of the Company on a poll
-- First quarter 2023 UPNEEQ® net product sales grew 49%, or $2.9 million, over the prior year period to $8.8 million -- -- Enhanced operating leverage with a 32%, or $7.9 million, reduction in first quarter 2023 total operating expenditures from the prior year -- -- Majority of aesthetic orders in the first quarter, or 54%, represented reorder activity -- -- Approximately 4,800 cumulative unique medical aesthetics practices had placed orders for UPNEEQ through the end of the first quarter, a 12% increase from prior quarter end -- -- UPNEEQ Won "Best Eye Drop for Drooping Lids" NewBeauty in 13th Annual Beauty Awards, selected from among 10,000 entrants -- BRIDGEWATER, N.J., M
BRIDGEWATER, N.J., May 04, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, today announced that the Company will release its first quarter 2023 financial results and provide a commercial update on Thursday, May 11, 2023, before U.S. financial markets open. Brian Markison, Chief Executive Officer, James "JD" Schaub, Chief Operating Officer, and Mike DePetris, Principal Accounting Officer, will host a conference call as follows: DateThursday, May 11, 2023Time 8:30 a.m. ETToll free (U.S.)800-579-2543International 7
BRIDGEWATER, N.J., April 03, 2023 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (NASDAQ:RVLP) ("RVL" or the "Company") announced today that its prescription eye drop Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected the winner in the professional treatment category as "Best Eye Drop for Drooping Lids" in the NewBeauty 13th Annual Beauty Awards. Upneeq is FDA approved for the treatment of acquired blepharoptosis (droopy eyelids) in adults. It is the second consecutive win for the brand. Upneeq® was awarded the "Best Innovation" in 2022 by this definitive authority in beauty. The 13th Annual NewBeauty Awards issue hits newsstands on April 4, 2023. Over 10,000
Gainers Apollomics (NASDAQ:APLM) stock increased by 23.6% to $2.15 during Friday's after-market session. The company's market cap stands at $192.3 million. GRI Bio (NASDAQ:GRI) stock increased by 11.39% to $1.27. The company's market cap stands at $3.7 million. Syros Pharmaceuticals (NASDAQ:SYRS) shares moved upwards by 8.14% to $2.39. The company's market cap stands at $49.4 million. TC BioPharm (Holdings) (NASDAQ:TCBP) shares moved upwards by 7.23% to $0.4. The company's market cap stands at $3.2 million. Renalytix (NASDAQ:RNLX) stock rose 6.8% to $1.3. The market value of their outstanding shares is at $61.8 million. Moleculin Biotech (NASDAQ:MBRX) stock moved upwards by 6.3% to $0.
Gainers XORTX Therapeutics Inc. (NASDAQ:XRTX) shares jumped 60.2% to $0.5101 after jumping 34% on Thursday. Lipella Pharmaceuticals Inc. (NASDAQ:LIPO) climbed 58.7% to $2.46. Lipella Pharmaceuticals announced FDA clearance of IND for LP-310 for oral lichen planus. Catalyst Biosciences, Inc. (NASDAQ:CBIO) jumped 44% to $0.5780. MMTec, Inc. (NASDAQ:MTC) gained 37.6% to $2.84 after jumping 51% on Thursday. MMTEC is scheduled to hold its 2023 annual meeting of shareholders on Nov. 10, 2023. Nouveau Monde Graphite Inc. (NYSE:NMG) surged 28% to $2.60 Aravive, Inc. (NASDAQ:ARAV) shares climbed 26.3% to $0.1780 after falling 15% on Thursday. HUB Cyber Security Ltd. (NASDAQ:HUBC) shares ju
Gainers Aravive (NASDAQ:ARAV) shares rose 67.5% to $0.24 during Friday's regular session. As of 13:30 EST, this security is trading at a volume of 90.0 million shares, making up 979.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $17.3 million. Lipella Pharmaceuticals (NASDAQ:LIPO) stock moved upwards by 42.27% to $2.29. Lipella Pharmaceuticals's stock is trading at a volume of 39.3 million shares as of 13:30 EST. This is 574673.5% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $13.2 million. Sagimet Biosciences (NASDAQ:SGMT) shares rose 25.27% to $5.72. As of 13:30 EST,
Gainers SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 36.4% to $1.0516. SeaStar medical shares jumped 70% on Wednesday after the FDA granted the company's Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. Outlook Therapeutics, Inc. (NASDAQ:OTLK) jumped 33.6% to $0.6304. MMTec, Inc. (NASDAQ:MTC) rose 32% to $1.7929. Atreca, Inc. (NASDAQ:BCEL) shares gained 28.8% to $0.3490. On Sept. 21, Atreca announced the termination of the lease at its corporate headquarters and the departure of the company's CFO. Spectral AI, Inc. (NASDAQ:MDAI) gained 26.7% to $3.2803. Spectral AI said that its DeepView SnapShot® Wound Imaging System is now
Gainers Ontrak (NASDAQ:OTRKP) shares moved upwards by 41.4% to $0.49 during Thursday's regular session. SeaStar Medical Holding (NASDAQ:ICU) stock rose 38.63% to $1.07. As of 13:30 EST, SeaStar Medical Holding's stock is trading at a volume of 113.1 million, which is 1149.9% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $20.7 million. Outlook Therapeutics (NASDAQ:OTLK) stock moved upwards by 35.58% to $0.64. As of 13:30 EST, Outlook Therapeutics's stock is trading at a volume of 106.5 million, which is 1616.6% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $166.4 million.
Gainers Shift Technologies, Inc. (NASDAQ:SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Treasure Global Inc. (NASDAQ:TGL) climbed 65.1% to $0.5150 after the company announced an AI robot designed to conduct extended-hour live commerce sessions on TikTok. SeaStar Medical Holding Corporation (NASDAQ:ICU) shares climbed 45.3% to $0.6589 after the FDA granted the company’s Selective Cytopheretic Device Breakthrough Device Designation for hepatorenal syndrome. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares gained 31.4% to $0.0670 after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12, the company receive
Gainers Biocept (NASDAQ:BIOC) stock moved upwards by 48.9% to $0.76 during Wednesday's pre-market session. The company's market cap stands at $1.9 million. RVL Pharmaceuticals (NASDAQ:RVLP) stock moved upwards by 47.05% to $0.07. The market value of their outstanding shares is at $8.3 million. Baudax Bio (NASDAQ:BXRX) shares moved upwards by 42.49% to $0.28. The market value of their outstanding shares is at $2.6 million. SeaStar Medical Holding (NASDAQ:ICU) shares rose 19.05% to $0.54. The market value of their outstanding shares is at $10.4 million. Synaptogenix (NASDAQ:SNPX) stock moved upwards by 16.31% to $0.37. The market value of their outstanding shares is at $3.7 million. Yiel
Gainers Biocept, Inc. (NASDAQ:BIOC) shares surged 91.8% to $0.98 in pre-market trading after falling over 6% on Tuesday. Biocept recently filed for Chapter 7 bankruptcy in the U.S. Bankruptcy Court for the District of Delaware. Shift Technologies, Inc. (NASDAQ:SFT) shares rose 74.4% to $0.1878 in pre-market trading. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection. Connexa Sports Technologies Inc. (NASDAQ:CNXA) shares gained 45% to $2.45 in pre-market trading after gaining around 4% on Tuesday. RVL Pharmaceuticals plc (NASDAQ:RVLP) shares climbed 41.2% to $0.0720 in pre-market trading after falling 12% on Tuesday. RVL Pharmaceuticals said on Oct. 12,
Gainers Biocept (NASDAQ:BIOC) shares moved upwards by 109.4% to $1.07 during Tuesday's after-market session. Trading volume for this security closed at 4.8 million, accounting for 264.8% of its average full-day volume over the last 100 days. The market value of their outstanding shares is at $2.8 million. Intelligent Bio Solutions (NASDAQ:INBS) shares moved upwards by 31.44% to $0.4. At the close, Intelligent Bio Solutions's trading volume reached 2.0 million shares. This is 1402.0% of its average volume over the last 100 days. The market value of their outstanding shares is at $1.8 million. RVL Pharmaceuticals (NASDAQ:RVLP) stock rose 17.45% to $0.06. RVL Pharmaceuticals's trading volume
Gainers MingZhu Logistics Holdings Limited (NASDAQ:YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. PCTEL, Inc. (NASDAQ:PCTI) climbed 47.3% to $6.86. On Friday, Amphenol Corp (NYSE:APH) inked a deal to acquire PCTEL for around $139.7 million. Almacenes Éxito S.A. (NYSE:EXTO) shares rose 32.6% to $6.66. MMTec, Inc. (NASDAQ:MTC) surged 30% to $0.7608. Tempest Therapeutics, Inc. (NASDAQ:TPST) gained 29% to $4.72. LQR House Inc. (NASDAQ:LQR) shares climbed 24.5% to $0.2148. LQR House announced that through its custom marketing campaign and strategic efforts, Von Payne Whiskey is now displayed on the shelves of the retail giant, Costco. Secoo Holding Limited (N